Canurta Naturals to Lead Operational Transition at FSOil Facility, Expanding cGMP Botanical Extraction Capacity in North America

Toronto, ON — January 12, 2025 – Canurta Naturals today announced that it has reached an agreement under which it will manage operation of FSOil’s large-scale botanical extraction facilities in Woodburn, Oregon. Under this new structure, the processing facility, select equipment, and key operational personnel will continue their work under Canurta Naturals, ensuring exceptional and consistent services for existing customers while strengthening North American supply of high-quality botanical ingredients.

Canurta Naturals USA will operate the cGMP CO₂ extraction and post-processing facilities in the Willamette Valley, with both supercritical and subcritical capabilities and certifications that include Current Good Manufacturing Practices, USDA Organic, U.S. Hemp Authority, and Kosher. Since 2017, FSOil has provided toll processing, bulk extracts, and finished product development for hemp and other plant-based functional ingredients.

View the Canurta Naturals Website

By integrating the manufacturing platform and experienced team, Canurta Naturals will expand its ability to deliver validated, science-first nutraceuticals focused on inflammation and cognitive health, and have the ability to improve extraction techniques to produce products which include rare hemp polyphenols such as cannflavins A and B. The transition is designed to maintain service for current customers while adding new capabilities in formulation, R&D, and commercialization. 

Existing customers will continue to be served by the same core operational team and facility in Woodburn, Oregon. Day-to-day production, quality systems, and service offerings—including CO₂ extraction, winterization, distillation, remediation, blending, and formulation—will continue, with additional support from Canurta Naturals’ product development and regulatory teams. 

Over time, the integrated operation is expected to expand beyond hemp into additional botanicals, supporting Canurta Naturals’ strategy to unlock under-utilized plant compounds for evidence-based nutraceuticals targeting inflammation, cognition, stress, and healthy aging. 

“Our priority has always been our customers and the integrity of the products made here. This operational transition ensures continuity, quality, and reliability, while honoring the work that went into building this platform. It’s rewarding to see the foundation we created continue to support customers and the industry,” said, Kathryn Ward, Chief Operating Officer of Canurta Naturals USA.  

Akeem Gardner, CEO of Canurta Inc added, “this integration strengthens our manufacturing backbone in North America and aligns with Canurta’s science-first approach to botanical development. Preserving operational excellence while expanding R&D, formulation, and regulatory capabilities was the priority—and this platform allows us to do exactly that.” 

About Canurta Naturals USA Inc. 

Canurta Naturals develops science-first nutraceuticals focused on cognitive and inflammatory health. By harnessing rare botanicals and patented technologies that unlock bioactive hemp polyphenols such as cannflavins A and B, Canurta Naturals delivers safe, clinically relevant products aimed at supporting inflammation, brain health, stress resilience, and everyday wellness. 

About Canurta Inc. 

Canurta Inc is an innovative biotechnology company dedicated to pioneering botanical therapeutics for inflammatory and neurodegenerative diseases. Utilizing its proprietary Polykye™ platform, Canurta develops rare bioactive botanical ingredients and multi-target formulations designed to address complex disease mechanisms with clinical rigor. The company's lead candidate, CNR-401, is advancing towards Phase 2 clinical trials targeting Amyotrophic Lateral Sclerosis (ALS), with a parallel strategy incorporating real-world evidence initiatives to accelerate global regulatory approval. 

About PharmaDrug Inc. 

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. 

For further information, please contact:
 Akeem Gardner, CEO of Canurta Inc akeem@canurta.com 

Caution Regarding Forward-Looking Information: 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward-looking statements in this press release relate to the Transaction, the holding of the Shareholder Meeting, the completion of the Second Tranche, the business of Canurta and the development of the Company's business. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.  

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals..  

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. 

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.  

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.